EAU 2022 | RESECT: variation in quality of TURBT and its impact on bladder cancer management

Kevin Gallagher, MBChB, Western General Hospital, Edinburgh, UK, discusses RESECT (NCT05154084), an observational study investigating the quality of transurethral resection of bladder tumour (TURBT) surgery for the diagnosis and treatment of non-muscle-invasive bladder cancer (NMIBC). The quality of TURBT surgery is known to impact subsequent patient outcomes, and there is evidence that TURBT surgery quality varies significantly both within and between countries. Dr Gallagher describes how RESECT is the first time that patient-level data is collected to demonstrate that this variation in quality exists and to show how such variation impacts patient outcomes such as progression rates and cancer recurrence. This interview took place at the European Association of Urology (EAU) Meeting 2022.